The Fort Worth Press - Drugmakers agree to US govt price talks amid pushback

USD -
AED 3.673042
AFN 67.000368
ALL 93.103989
AMD 388.250403
ANG 1.803449
AOA 912.000367
ARS 998.514239
AUD 1.547161
AWG 1.795
AZN 1.70397
BAM 1.850279
BBD 2.020472
BDT 119.580334
BGN 1.852849
BHD 0.376902
BIF 2898.5
BMD 1
BND 1.341507
BOB 6.914723
BRL 5.796904
BSD 1.000634
BTN 84.073433
BWP 13.679968
BYN 3.274772
BYR 19600
BZD 2.017086
CAD 1.40779
CDF 2865.000362
CHF 0.886704
CLF 0.035534
CLP 980.503912
CNY 7.232504
CNH 7.23455
COP 4442.25
CRC 509.261887
CUC 1
CUP 26.5
CVE 104.850394
CZK 23.936304
DJF 177.720393
DKK 7.070475
DOP 60.403884
DZD 133.36178
EGP 49.356804
ERN 15
ETB 122.000358
EUR 0.94797
FJD 2.27595
FKP 0.789317
GBP 0.791875
GEL 2.73504
GGP 0.789317
GHS 15.95039
GIP 0.789317
GMD 71.000355
GNF 8630.000355
GTQ 7.728257
GYD 209.258103
HKD 7.78573
HNL 25.12504
HRK 7.133259
HTG 131.547827
HUF 386.85904
IDR 15900
ILS 3.749604
IMP 0.789317
INR 84.44345
IQD 1310.5
IRR 42092.503816
ISK 137.550386
JEP 0.789317
JMD 158.916965
JOD 0.709104
JPY 154.17704
KES 129.503801
KGS 86.503799
KHR 4050.00035
KMF 466.575039
KPW 899.999621
KRW 1395.970383
KWD 0.30752
KYD 0.833948
KZT 497.28482
LAK 21953.000349
LBP 89550.000349
LKR 292.337966
LRD 184.000348
LSL 18.220381
LTL 2.95274
LVL 0.60489
LYD 4.875039
MAD 10.013504
MDL 18.182248
MGA 4665.000347
MKD 58.285952
MMK 3247.960992
MNT 3397.999946
MOP 8.023973
MRU 39.960379
MUR 47.210378
MVR 15.450378
MWK 1736.000345
MXN 20.347039
MYR 4.470504
MZN 63.903729
NAD 18.220377
NGN 1665.000344
NIO 36.765039
NOK 11.080704
NPR 134.517795
NZD 1.70461
OMR 0.385025
PAB 1.000643
PEN 3.803039
PGK 4.01975
PHP 58.726038
PKR 277.703701
PLN 4.091755
PYG 7807.725419
QAR 3.640604
RON 4.717904
RSD 110.903038
RUB 100.051477
RWF 1369
SAR 3.755981
SBD 8.390419
SCR 14.705038
SDG 601.503676
SEK 10.96796
SGD 1.341675
SHP 0.789317
SLE 22.603667
SLL 20969.504736
SOS 571.503662
SRD 35.315504
STD 20697.981008
SVC 8.755664
SYP 2512.529858
SZL 18.220369
THB 34.816504
TJS 10.667159
TMT 3.51
TND 3.157504
TOP 2.342104
TRY 34.438704
TTD 6.794573
TWD 32.504504
TZS 2660.000335
UAH 41.333087
UGX 3672.554232
UYU 42.941477
UZS 12835.000334
VES 45.450217
VND 25390
VUV 118.722009
WST 2.791591
XAF 620.560244
XAG 0.033031
XAU 0.00039
XCD 2.70255
XDR 0.753817
XOF 619.503595
XPF 113.550363
YER 249.875037
ZAR 18.207037
ZMK 9001.203587
ZMW 27.473463
ZWL 321.999592
  • CMSC

    -0.0300

    24.52

    -0.12%

  • SCS

    -0.0200

    13.25

    -0.15%

  • RIO

    0.4100

    60.84

    +0.67%

  • NGG

    0.1830

    62.553

    +0.29%

  • GSK

    -0.5310

    33.4699

    -1.59%

  • AZN

    -1.5300

    63.51

    -2.41%

  • BCC

    -0.8750

    139.475

    -0.63%

  • RYCEF

    0.0100

    6.8

    +0.15%

  • JRI

    -0.0415

    13.035

    -0.32%

  • BTI

    0.8410

    36.331

    +2.31%

  • BCE

    0.0250

    26.865

    +0.09%

  • BP

    -0.2000

    28.85

    -0.69%

  • CMSD

    0.0422

    24.4

    +0.17%

  • RBGPF

    1.6500

    61.84

    +2.67%

  • VOD

    0.0700

    8.75

    +0.8%

  • RELX

    -1.5350

    44.415

    -3.46%

Drugmakers agree to US govt price talks amid pushback
Drugmakers agree to US govt price talks amid pushback / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File

Drugmakers agree to US govt price talks amid pushback

Major drugmakers have grudgingly agreed to negotiate on reducing prices for 10 medicines, the White House said Tuesday, a key element in President Joe Biden's push to lower healthcare costs ahead of the 2024 election.

Text size:

Under the initiative, the federal government is using new powers to negotiate the prices of drugs covered by Medicare, the massive health insurance program for people 65 and older.

Biden's landmark Inflation Reduction Act (IRA), the major legislative package of energy transition policy and social reforms he signed last year, allowed Medicare to begin negotiating drug prices for the first time in its nearly 60-year existence.

The White House said makers of 10 medicines for serious illnesses, selected earlier in the year for price negotiations with the US government, have all agreed to participate in the talks ahead of an October 1 deadline.

The drugs include Farxiga by AstraZeneca used against diabetes, and Entresto by Novartis used to treat heart failure.

The treatments also include the anticoagulant Eliquis, used by more than 3.7 million Medicare beneficiaries.

The government is limited at first to choosing only 10 drugs for price negotiations, but can expand the program in subsequent years.

- 'Only viable option' -

Pharmaceutical firms have pushed back against the initiative, coming on board as they said they had no choice.

There are steep consequences for not participating in talks -- manufacturers that fail to comply with the program could face tax penalties.

Novartis said in a statement that it signed the negotiation program agreement as "this was our only viable option."

"If we had not signed the agreement, Novartis would face excessive and crippling fines," a spokesman added.

The company argues that the price-setting provisions are "unconstitutional."

Some firms like Amgen said they signed the manufacturer agreement for the program "in light of the statutory deadline."

But Amgen added it believes the scheme "is unlawful and will impede medical progress" on key therapies.

A Johnson & Johnson spokesperson told AFP: "We continue to believe the IRA's drug price-setting provisions are damaging to the innovation ecosystem."

- Lawsuits -

Several companies have taken legal action challenging the provisions.

Novo Nordisk said these "subject the company's medicines to unconstitutional government-imposed price controls" in announcing its lawsuit last Friday.

Merck in June filed a suit calling the program an unconstitutional "extortion" that would harm pharmaceutical innovation.

"In total, the 10 drugs selected for negotiation accounted for $3.4 billion in out-of-pocket costs for an estimated nine million Medicare enrollees in 2022," the White House said Tuesday.

It called the latest development a "major step towards lower health care costs for seniors and families."

The United States pays on average 2.5 times more for prescription drugs than other developed countries such as France, according to a Rand Corporation study.

Biden, who is campaigning for reelection with a heavy focus on easing voters' financial woes, hailed the price negotiation developments last year as potentially life-altering for millions of Americans.

The change in prices for the 10 drugs are not set to come into effect until January 2026.

Medicare is set to negotiate prices for up to 60 drugs in the next four years, and up to an additional 20 drugs each year after that.

L.Holland--TFWP